A pivotal trial to investigate the efficacy of affinity enhanced T-cell therapy targeting NY-ESO (NY-ESO-1/LAGE-1-specific T-cells) in synovial sarcoma
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2016
At a glance
- Drugs NY-ESO-1c259 TCR-transduced lymphocytes (Primary)
- Indications Synovial sarcoma
- Focus Therapeutic Use
- 08 Aug 2016 According to an Adaptimmune media release, initiation of this trial has been delayed until mid-2017.
- 22 Apr 2016 According to Adaptimmune media release, company plans to start this study in 4Q of 2016/1Q 2017.
- 10 Feb 2016 New trial record